The strong beat and raised guidance confirm accelerating commercial momentum for BRUKINSA and improving operating leverage. Watch for upcoming FDA regulatory actions on TEVIMBRA (2H 2026) and sonrotoclax NDA (1H 2026) as potential catalysts. The stock should re-rate higher on the sustained profitability inflection.
Price Chart
Executive Summary
BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA global sales of $1.1B (+38% YoY). GAAP diluted EPS was $1.96 per ADS, a massive swing from $0.01 in the prior year. The company raised its full-year 2026 revenue guidance to $6.3B-$6.5B (from $6.2B-$6.4B) and its GAAP operating income guidance to $750M-$850M (from $700M-$800M), signaling accelerating profitability.
Key Financial Metrics
Key Facts
- Total Q1 2026 revenue of $1.51B, up 35% YoY from $1.12B
- BRUKINSA global sales of $1.1B, up 38% YoY; U.S. sales $761M, up 35%
- GAAP net income of $227M vs $1.3M in Q1 2025; GAAP diluted EPS $1.96 per ADS vs $0.01
- Gross margin expanded to 89% from 85% YoY on favorable product mix and cost improvements
- Full-year 2026 revenue guidance raised to $6.3B-$6.5B from $6.2B-$6.4B
- GAAP operating income guidance raised to $750M-$850M from $700M-$800M
- Free cash flow of $161M vs -$12M in Q1 2025, a $173M improvement
- TEVIMBRA global sales of $206M, up 20% YoY; Amgen in-licensed products $142M, up 25%
Financial Impact
Q1 revenue beat consensus by ~$70M (4.9%); GAAP net income swung from $1.3M to $227M; guidance raised by $100M at midpoint
Risk Factors
- R&D and SG&A expenses grew 12% and 21% respectively, outpacing revenue growth in absolute dollars
- Foreign exchange rate assumptions in guidance could be impacted by currency volatility
- Potential valuation allowance reversal creates uncertainty in income tax expense timing and magnitude
- Heavy reliance on BRUKINSA for revenue growth; competitive pressure from other BTK inhibitors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-030866 |
| Document: bgne-20260506.htm | 0001628280-26-030866 |
| Document: 0001628280-26-030866-index-headers.html | 0001628280-26-030866 |
| Document: 0001628280-26-030866-index.html | 0001628280-26-030866 |
| Document: 0001628280-26-030866.txt | 0001628280-26-030866 |
| 8-K Data (Synthetic) | 0001628280-26-030866 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 144 | $21.95 $21.95 | · 0.00% | ▼ −4.08% | $21.95 (−0.00%) |
May 6, 2026 24w ago | 8-K | $22.50 $21.95 | ▼ −2.48% | ▼ −4.54% | $21.95 (−2.48%) |
Apr 14, 2026 28w ago | 8-K | $22.50 $21.95 | ▼ −2.48% | ▼ −11.00% | $21.95 (−2.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers